leadf
logo-loader
viewRevive Therapeutics

Revive Therapeutics to start enrolling patients in Phase 3 coronavirus trial of Bucillamine

The trial will enroll as many as 1,000 patients that will be randomized 1:1:1 to receive Bucillamine 100 mg, Bucillamine 200 mg or a placebo three times a day for up to 14 days

Virus graphic
The company has finalized agreements with five clinical sites and is working out the details with an additional 10 sites

Revive Therapeutics Ltd (CSE:RVV) (OTC:RVVTF) has selected five sites in Florida, Texas and California where it will begin enrolling patients for a Phase 3 trial of its drug Bucillamine in patient with mild-to-moderate cases of the coronavirus (COVID-19).

The company has finalized agreements with five clinical sites and is working out the details with an additional 10 sites in those states, as well as in Arizona and Ohio. Patient enrollment is expected to begin in October, the company said.

The Phase 3 trial will enroll as many as 1,000 patients that will be randomized 1:1:1 to receive Bucillamine 100 mg, Bucillamine 200 mg or a placebo three times a day for up to 14 days. 

READ: Revive Therapeutics expands psychedelic product pipeline, advances clinical study to evaluate psilocybin in adults with methamphetamine use disorder

The plan is to compare the frequency of hospitalization or death in patients receiving Bucillamine with those receiving placebo. The primary endpoint is the proportion of patients meeting a composite endpoint of hospitalization or death after four weeks.

“We have made significant progress in advancing the Phase 3 clinical trial since the FDA approval allowed us to proceed with the study, and we are expanding on and engaging with clinical sites in high prevalence COVID-19 infected states, which will enable us to meet our enrollment goals and expedite the potential FDA approval and commercialization of Bucillamine for the treatment of COVID-19,” CEO Michael Frank said in a statement.

An interim analysis will be performed by an Independent Data and Safety Monitoring Board (DSMB) after 210 patients have been treated and followed up for 28 days after randomization, the company said. The better performing Bucillamine dose at the interim analysis will be selected and patients will then be randomized 2:1 to the selected Bucillamine dose or placebo. 

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Revive Therapeutics

Price: 0.21 CAD

CSE:RVV
Market: CSE
Market Cap: $34.43 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Revive Therapeutics named herein, including the promotion by the Company of Revive Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Revive Therapeutics: Analyst sees 'substantial upside potential' as key...

Proactive Research analyst Ed Stacey says Revive Therapeutics (CSE:RVV)(OTCQB:RVVTF) is a speciality life sciences company focussed on repurposing drugs for rare and infectious diseases and has a pipeline of of three main platforms. One of them is Bucillamine (BUC) which is a medication with a...

on 06/30/2020

2 min read